Japan Diabetes Drugs And Devices Market Size (2024 - 2029)

The market size for diabetes drugs and devices in Japan is projected to experience growth over the forecast period, driven by the increasing prevalence of diabetes, particularly type 2 diabetes, which is linked to lifestyle factors such as obesity and sedentary behavior. The rising diabetes population poses challenges for Japan's healthcare system, necessitating comprehensive public health strategies to address prevention and access to healthcare services. These factors are expected to contribute to the expansion of the market.

INSTANT ACCESS

Market Size of Japan Diabetes Drugs And Devices Industry

Japan Diabetes Drugs And Devices Market Summary
Study Period 2019 - 2029
Base Year For Estimation 2023
Forecast Data Period 2024 - 2029
Market Size (2024) USD 4.80 Billion
Market Size (2029) USD 6.40 Billion
CAGR (2024 - 2029) > 3.20 %

Major Players

Japan Diabetes Drugs And Devices Market Major Players

*Disclaimer: Major Players sorted in no particular order

Japan Diabetes Drugs and Devices Market Analysis

The Japan Diabetes Drugs And Devices Market size is estimated at USD 4.80 billion in 2024, and is expected to reach USD 6.40 billion by 2029, growing at a CAGR of greater than 3.20% during the forecast period (2024-2029).

Japan's diabetes drugs and devices market is poised for significant growth through the forecast period, driven by a rising prevalence of diabetes and proactive initiatives from companies, including product development and expanding production capacities.

Diabetes drugs and devices are crucial in monitoring and managing blood glucose levels. With Japan's diabetic population on the rise, companies are set to see an expanding user base. According to the IDF Diabetes Atlas, Japan is projected to have around 10,542.7 thousand individuals with diabetes by 2030; the number is expected to reach 10,117.9 thousand by 2045.

Recognizing the widening gap between the demand and supply of diabetic drugs, several companies are seizing the opportunity. For instance, in June 2024, Eli Lilly and Company made significant investments to boost its production capacity for drugs targeting obesity and diabetes. This move came as the company lifted restrictions on shipping its flagship diabetes drug, Manjaro, in Japan. By enhancing its production capabilities, Eli Lilly aims to meet the escalating demand for diabetes drugs, especially in light of limited supplies at the national level.

In May 2024, the Japan Diabetes Society published guidelines emphasizing the safe use of diabetes drugs, particularly Incretin-Related Drugs. This initiative was prompted by the rising adoption of GLP-1 receptor agonists, known for their efficacy in blood sugar management and weight reduction. These drugs have also shown promising results in addressing diabetes-related kidney and cardiovascular diseases, further bolstered by the introduction of orally administered formulations.

The diabetes drugs and devices market in Japan is on a robust growth trajectory. The increasing prevalence of diabetes, coupled with strategic initiatives by companies and regulatory support, is expected to drive market expansion. This dynamic environment presents significant opportunities for stakeholders in the diabetes care sector.

Japan Diabetes Drugs and Devices Industry Segmentation

Patients with type 1 diabetes must be given insulin because their pancreas cannot process it. To control blood sugar levels, insulin must be given several times a day, such as when eating or drinking. Many people with type 2 diabetes also need to take antidiabetic drugs. These drugs include diabetes medications and injections such as insulin.

Japan's diabetes drugs and devices market is segmented into devices and drugs. By devices, the market is segmented into monitoring devices and management devices. Monitoring devices include self-monitoring blood glucose devices and continuous blood glucose monitoring. Management devices include insulin pumps, insulin syringes, disposable pens, and others. By drugs, the market is segmented into oral anti-diabetes drugs, insulin drugs, and others. For each segment, the market sizing and forecasts were made on the basis of revenue (USD).

By Product Type
Devices
Monitoring Devices
Self-Monitoring Blood Glucose Devices
Continuous Blood Glucose Monitoring
Management Devices
Insulin Pump
Insulin Syringes
Disposable Pens
Others
Drugs
Oral Anti-diabetes Drugs
Insulin Drugs
Others
Need A Different Region Or Segment?
Customize Now

Japan Diabetes Drugs And Devices Market Size Summary

The Japan diabetes drugs and devices market is poised for significant growth, driven by the increasing prevalence of diabetes, particularly type 2 diabetes, which accounts for the majority of cases in the country. This rise is attributed to factors such as rapid urbanization, sedentary lifestyles, unhealthy dietary habits, and genetic predispositions. The healthcare system in Japan faces challenges due to the associated complications of diabetes, including cardiovascular diseases and kidney disorders, which place a substantial burden on healthcare resources. To combat this epidemic, comprehensive public health strategies focusing on prevention, early detection, and lifestyle modification are essential. The market is expected to expand as technological advancements in diabetes management devices, such as continuous glucose monitoring sensors, improve their affordability and user-friendliness.

The Japanese healthcare system, supported by a well-developed health insurance framework, covers all medical expenses for diabetes, facilitating access to necessary treatments and medications. Oral antidiabetic agents are widely used due to their efficacy, safety, and ease of use, making them a preferred choice for managing type 2 diabetes. The increasing prevalence of diabetes across all age groups, coupled with the economic burden it imposes, underscores the importance of effective diabetes management solutions. Major companies in the market are engaging in strategic partnerships and investments in research and development to enhance their product offerings and maintain market dominance. These efforts, along with government initiatives aimed at raising public awareness and promoting preventive measures, are expected to drive the growth of the diabetes drugs and devices market in Japan over the forecast period.

Explore More

Japan Diabetes Drugs And Devices Market Size - Table of Contents

  1. 1. MARKET DYNAMICS

    1. 1.1 Market Overview

    2. 1.2 Market Dynamics

      1. 1.2.1 Market Drivers

        1. 1.2.1.1 Rising Diabetes Prevalence In The Country

        2. 1.2.1.2 Growing Strategic Initiatives By The Government

      2. 1.2.2 Market Restraints

        1. 1.2.2.1 Limited Availability of Affordable Drug Delivery Devices In The Country

    3. 1.3 Porter's Five Forces Analysis

      1. 1.3.1 Bargaining Power of Suppliers

      2. 1.3.2 Bargaining Power of Consumers

      3. 1.3.3 Threat of New Entrants

      4. 1.3.4 Threat of Substitute Products and Services

      5. 1.3.5 Intensity of Competitive Rivalry

  2. 2. MARKET SEGMENTATION (Market Size by Value - USD)

    1. 2.1 By Product Type

      1. 2.1.1 Devices

        1. 2.1.1.1 Monitoring Devices

          1. 2.1.1.1.1 Self-Monitoring Blood Glucose Devices

          2. 2.1.1.1.2 Continuous Blood Glucose Monitoring

        2. 2.1.1.2 Management Devices

          1. 2.1.1.2.1 Insulin Pump

          2. 2.1.1.2.2 Insulin Syringes

          3. 2.1.1.2.3 Disposable Pens

          4. 2.1.1.2.4 Others

      2. 2.1.2 Drugs

        1. 2.1.2.1 Oral Anti-diabetes Drugs

        2. 2.1.2.2 Insulin Drugs

        3. 2.1.2.3 Others

Japan Diabetes Drugs And Devices Market Size FAQs

The Japan Diabetes Drugs And Devices Market size is expected to reach USD 4.80 billion in 2024 and grow at a CAGR of greater than 3.20% to reach USD 6.40 billion by 2029.

In 2024, the Japan Diabetes Drugs And Devices Market size is expected to reach USD 4.80 billion.

Japan Diabetes Drugs and Devices Market Size & Share Analysis - Growth Trends & Forecasts (2024 - 2029)